Zealand Pharma reports on lixisenatide trial

Wednesday 7 December 2011

Zealand Pharma A/S said that the latest clinical data for its prospective type 2 diabetes treatment, lixisenatide (Lyxumia) in combination with long-acting insulin, showed a significant reduction in plasma glucose concentrations (HbA1c).

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Denmark